NanoString Technologies, Inc. (NSTG)
(Delayed Data from NSDQ)
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Will NanoString Technologies Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NanoString Technologies.
NanoString Technologies (NSTG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -12.28% and 9.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NanoString Technologies (NSTG) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -3.64% and 4.64%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will NanoString Technologies (NSTG) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -6.15% and 8.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?
by Zacks Equity Research
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
NanoString Technologies (NSTG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
NanoString (NSTG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Can Dental Growth Drive Henry Schein's (HSIC) Q1 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is consistently riding on segmental strength at Dental, Medical and Technology plus Value-Added Services.
Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?
by Zacks Equity Research
Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.
Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.
Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?
by Zacks Equity Research
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
by Zacks Equity Research
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?
by Zacks Equity Research
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
by Zacks Equity Research
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?
by Zacks Equity Research
LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.
Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Meet, Zai Lab, NanoString Technologies, OSI Systems and AudioEye
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
5 Stocks With Recent Price Strength to Enhance Your Return
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.